JNJ vs ABBV
JNJ and ABBV side by side — valuation & fundamentals (public data).
Key statistics
| Metric | JNJJohnson & Johnson | ABBVAbbVie Inc. |
|---|---|---|
| Market cap | $618.05B | $443.25B |
| P/E (TTM) | 29.8 | 123.6 |
| P/B | 7.27 | — |
| P/S | 6.6x | 7.2x |
| Dividend yield | 2.00% | 2.63% |
| Revenue | $97.93B(TTM) | $61.16B(TTM) |
| Revenue growth (YoY) | 6.0% | 8.6% |
| Net income | $21.04B(TTM) | $3.63B(TTM) |
| Earnings growth (YoY) | 90.6% | -1.2% |
| EPS, diluted | $8.62(TTM) | $2.03(TTM) |
| EBIT margin | 22.9% | 24.6% |
| ROE | 31.5% | — |
| ROIC | 16.1% | 20.0% |
| Piotroski F | 6/9 | — |
| 1y total return | +58.7% | +36.2% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: JNJ vs ABBV
| Metric | JNJ | ABBV |
|---|---|---|
| End value | $31.1K | $67.6K |
| Total return | +211.5% | +575.8% |
| CAGR | +11.6% | +20.3% |
| Volatility | 18.5% | 25.8% |
| Sharpe | 0.48 | 0.70 |
| Sortino | 0.68 | 0.98 |
| Max drawdown | -27.4% | -45.1% |
Based on 2600 common trading days, 2016-03-30 → 2026-07-31 · risk-free 3.83% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)